A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Infliximab
DRUG: Methotrexate
DRUG: Methylprednisolone
DRUG: Ocrelizumab
DRUG: Placebo

Sponsor

Genentech, Inc.